XBIO (Xenetic Biosciences) Beginning Cash Position: $7.35 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XBIO Xenetic Biosciences Inc XBIO
83 GF Score
Price $3.79
GF Value $3.77
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Xenetic Biosciences Beginning Cash Position?

Xenetic Biosciences XBIO +2.09% 83 Beginning Cash Position is $7.35 Mil as of Jun. 2026. GuruFocus rates XBIO with a GF Score™ of 83/100 and a GF Value™ of $3.77 (Fairly Valued). The stock has 2 warning signs investors should review.

Xenetic Biosciences's Beginning Cash Position for the quarter that ended in Jun. 2026 was $7.35 Mil.

Xenetic Biosciences's quarterly Beginning Cash Position declined from Dec. 2025 ($8.13 Mil) to Mar. 2026 ($7.88 Mil) and declined from Mar. 2026 ($7.88 Mil) to Jun. 2026 ($7.35 Mil).

Xenetic Biosciences's annual Beginning Cash Position declined from Dec. 2023 ($13.10 Mil) to Dec. 2024 ($8.98 Mil) and declined from Dec. 2024 ($8.98 Mil) to Dec. 2025 ($6.17 Mil).

Xenetic Biosciences Beginning Cash Position Related Terms

Xenetic Biosciences Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Xenetic Biosciences's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xenetic Biosciences Beginning Cash Position Chart

Xenetic Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.53 18.24 13.10 8.98 6.17

Xenetic Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.16 4.78 8.13 7.88 7.35
XBIO
83GF Score
Xenetic Biosciences Inc XBIO
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xenetic Biosciences Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $7.35 Mil mean?
Xenetic Biosciences (XBIO) has a Beginning Cash Position of $7.35 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Xenetic Biosciences and its competitors.
Is Xenetic Biosciences' Beginning Cash Position too high?
Xenetic Biosciences' current Beginning Cash Position is $7.35 Mil. Overall, Xenetic Biosciences has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Xenetic Biosciences' Beginning Cash Position compare to ADIL and PULM?
Xenetic Biosciences' Beginning Cash Position of $7.35 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Xenetic Biosciences and its competitors. Xenetic Biosciences's current Beginning Cash Position is $7.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xenetic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Xenetic Biosciences (XBIO) is currently considered Fairly Valued. The stock's GF Value™ is $3.77, compared to a current price of $3.79 — trading 0.5% above its estimated fair value. The current Beginning Cash Position is $7.35 Mil. Xenetic Biosciences' overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Xenetic Biosciences (XBIO), the current Beginning Cash Position is $7.35 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xenetic Biosciences (XBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Xenetic Biosciences stock appears to be overvalued. The current stock price of $3.79 is trading 0.5% above its estimated GF Value™ of $3.77. GuruFocus considers Xenetic Biosciences to be Fairly Valued.

Key valuation signals for XBIO:

  • Beginning Cash Position: $7.35 Mil
  • GF Value™: $3.77 vs. price of $3.79 (0.5% above fair value)
  • GF Score™: 83/100 with 2 warning signs

No single metric tells the full story. See the XBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xenetic Biosciences Business Description

Address 945 Concord Street, Framingham, MA, USA, 01701
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
83GF Score

Get the complete analysis for XBIO

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.79
Price
$3.77
GF Value